China's vaccines are included in WHO's "emergency use list", and neutralizing an
Release time: 2021-05-08

On May 7, 2021, the World Health Organization (WHO) announced that the new crown vaccine developed by the Beijing Institute of Biological Products of China will be included in the WHO "emergency use list". Live vaccines.


The WHO has urgently authorized the adenovirus vector vaccine of AstraZeneca in the United Kingdom, the mRNA vaccine of Pfizer/BioNTech of the United States, the adenovirus vector vaccine of Johnson & Johnson of the United States and the mRNA vaccine of Moderna of the United States.


According to the data released by the WHO, the Chinese biological BBIBP-CorV vaccine has 78.1% protection against symptomatic COVID-19. This conclusion applies to people aged 18-59 without risk factors.


In order to further clarify the degree of protection after vaccination, China's biological sub-diagnostic platform Shanghai Jienuo (Shanghai Jienuo Biotechnology Co., Ltd.) and Shanghai Liangrun (Shanghai Liangrun Biomedical Technology Co., Ltd.) have reached a strategic cooperation to jointly develop vaccines accompanying the new crown vaccine. Neutralizing Antibody Elisa Detection Kit.


Neutralizing antibodies recognize virus surface proteins, block the binding of the virus to specific receptors on the cell surface, and prevent the virus from continuing to invade human cells. After dozens of R&D personnel work day by day, thousands of people have completed real-world verification studies, and the consistency rate with the "gold standard" vaccine neutralization experiment is >90%.


Zhang Yuntao, vice president of China Biotechnology, said: "Many hospitals do not detect neutralizing antibodies for new coronavirus antibody detection reagents. The persistence of antibodies we are talking about now refers to neutralizing antibodies." The neutralizing antibody of the new crown is to compete for binding to the S protein on the surface of the virus, preventing the virus from invading cells. Through the detection of neutralizing antibodies blocking the binding of new crown S1-RBD and ACE2, the inhibition rate and content were determined, and the protective efficacy of the vaccine on individuals was evaluated.


The neutralizing antibody kit was certified by CE a few months ago and was listed on the "export white list" of the Ministry of Commerce. With the export of China's vaccines, more than 300,000 neutralizing antibody reagents have helped overseas fight against the epidemic.

Hotline: 021-50680557

Address: 5th Floor, Building 2, No. 271, Gangao Road,
Shanghai Pilot Free Trade Zone, China